

1 **Prediction of antidepressant side effects in the Genetic Link to Anxiety and**  
2 **Depression Study**

3  
4 Danyang Li, PhD 1\*, Yuhao Lin, MSc 1, Helena L. Davies, PhD 1,2,3, Johan Källberg  
5 Zvrskovec, MSc 1, Rujia Wang, PhD 1, Chérie Armour, PhD 4, Ian R. Jones, PhD 5,  
6 Andrew M. McIntosh, MD 6, Nathalie Kingston, PhD 7, John R. Bradley, PhD 7,  
7 Christopher Hübel, PhD 1,8, Gursharan Kalsi, PhD 1,9, Jonathan R. I. Coleman, PhD  
8 1,9, the NIHR BioResource consortium, Matthew Hotopf, PhD 9,10, Thalia C. Eley,  
9 PhD 1, Evangelos Vassos, PhD 1, Raquel Iniesta, PhD 11,12, Gerome Breen, PhD 1\*

10

11 1 = Social, Genetic and Developmental Psychiatry Centre, King's College London,  
12 London

13 2 = Mental Health Center Ballerup, Copenhagen University Hospital – Mental Health  
14 Services CPH, Center for Eating and feeding Disorders Research, Denmark

15 3 = Mental Health Center Sct. Hans, Mental Health Services Copenhagen, Roskilde,  
16 Institute of Biological Psychiatry, Denmark

17 4 = Research Centre for Stress Trauma and Related Conditions (STARC), School of  
18 Psychology, Queen's University Belfast, Belfast

19 5 = National Centre for Mental Health, Cardiff University, Cardiff

20 6 = Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh,  
21 Edinburgh

22 7 = University of Cambridge, Cambridge

23 8 = National Centre for Register-based Research, Aarhus University, Aarhus

24 9 = UK National Institute for Health and Social Care Research (NIHR) Biomedical  
25 Research Centre for Mental Health, South London and Maudsley Hospital, London

26 10 = Institute of Psychiatry, Psychology and Neuroscience, King's College London,  
27 London

28 11 = Department of Biostatistics & Health Informatics, King's College London, London

29 12 = King's Institute for Artificial Intelligence, King's College London, London

30 \* = Corresponding authors

31 **Abstract:**

32 Antidepressants are the most common treatment for moderate or severe depression.  
33 Side effects are crucial indicators for antidepressants, but their occurrence varies  
34 widely among individuals. In this study, we leveraged genetic and medical data from  
35 self-reported questionnaires in the Genetic Links to Anxiety and Depression (GLAD)  
36 study to build prediction models of side effects and subsequent discontinuation across  
37 three antidepressant classes (SSRI, SNRI, tricyclic antidepressant (TCA)) at the first  
38 and the last (most recent) year of prescription. We included 259 predictors spanning  
39 genetic, clinical, illness, demographic, and antidepressant information. Six prediction  
40 models were trained, and their performance was compared. The final dataset  
41 comprised 4,354 individuals taking SSRI in the first prescription and 3,414 taking SSRI,  
42 SNRI or TCA in the last year of prescription. In the first year, the best area under the  
43 receiver operating characteristic curve (AUROC) for predicting SSRI discontinuation  
44 and side effects were 0.65 and 0.60. In the last year of SSRI prescription, the highest  
45 AUROC reached 0.73 for discontinuation and 0.87 for side effects. Models for  
46 predicting discontinuation and side effects of SNRI and TCA showed comparable  
47 performance. The history of side effects and discontinuation of antidepressant use  
48 were the most influential predictors of the outcomes in the last year of prescription.  
49 When examining 30 common antidepressant side effect symptoms, most of them were  
50 differentially prevalent between antidepressant classes. Our findings suggested the  
51 feasibility of predicting antidepressant side effects using a self-reported questionnaire,  
52 particularly for the last prescription. These results could contribute valuable insights  
53 for the development of clinical decisions aimed at optimising treatment selection with  
54 enhanced tolerability but require replication in medical record linkage or prospective  
55 data.

## 56 Introduction

57 Antidepressants are commonly prescribed medications, but both clinicians and their patients  
58 face uncertainty and concerns due to a lack of ability to accurately predict who will  
59 experience side effects. The majority of individuals taking antidepressants report  
60 experiencing at least one side effect<sup>1</sup>. In clinical trials, more than half of individuals  
61 discontinue medication within six months of starting treatment, with side effects being the  
62 most commonly cited contributing factor<sup>2</sup>. Side effects often result in staged and/or  
63 inadequate dosing, which is associated with a lack of remission or delayed remission<sup>1</sup>. Some  
64 side effects, such as fatigue, sleep change, and cognitive impairment phenomenologically  
65 overlap with depression symptoms and related comorbidities, such as anxiety. This overlap  
66 further complicates treatment decisions such as dose adjustment or the selection of  
67 appropriate initial or alternative medications.

68  
69 Tricyclic antidepressants (TCAs) were the dominant medications used to treat depression  
70 before the 1990s. Currently, second-generation antidepressants such as selective serotonin  
71 reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are  
72 first-line treatments for depression. All antidepressants operate by targeting monoamine  
73 neurotransmitters to increase activation of postsynaptic receptors<sup>3</sup>. Individuals taking TCAs  
74 are more likely to discontinue treatment, to experience lower tolerability and increased  
75 cardiac side effects compared to those taking second-generation antidepressants<sup>4,5</sup>.  
76 Conversely, side effects such as sexual dysfunction, insomnia, nausea, irritability, and  
77 anxiety are more prominent response to SSRIs and SNRIs<sup>6</sup>. Nevertheless, clarity over which  
78 side effect symptoms are specific to different antidepressants is lacking.

79  
80 Within the same type of drugs, there is considerable inter-individual variance in side effect  
81 occurrence and severity. Various factors, including sex<sup>7</sup> and clinical features like depression  
82 severity<sup>8</sup>, have been associated with antidepressant tolerability and adherence.  
83 Pharmacogenomic testing is an emerging strategy to inform medication selection and dose  
84 decisions based on individual genetic variations. Variants such as those found in the  
85 cytochrome P450 genes *CYP2C19* and *CYP2D6* are linked to antidepressant metabolism  
86 and clearance. They can cause differences in enzyme activity that influence antidepressant  
87 response and side effects, although their reported effects are inconsistent among studies<sup>9,10</sup>.  
88 In addition, polygenic scores (PGSs) related to depression have been reported to be  
89 predictive of side effects that overlap with depressive symptoms, such as suicidality and  
90 anxiety<sup>11</sup>. The multi-PGS framework allows combined analysis of multiple relevant PGSs  
91 associated with a specific trait or outcome, with the aim of improved prediction accuracy  
92 compared to a single PGS<sup>12,13</sup>.

93  
94 Side effects could be influenced by a combination of many factors spanning attributions,  
95 illness representations, personality, clinical, genetic, and social factors. In contrast with  
96 traditional statistical models, machine learning methods can optimally be used for prediction  
97 analyses involving large datasets that show complex interrelationships and are very often  
98 high-dimensional. Machine learning can effectively capture both linear and non-linear  
99 relationships across multiple data sources<sup>14,15</sup>. These methods employ data-resampling  
100 procedures in holdout samples to estimate models' parameters and to internally validate



127 All participants in this study were from the Genetic Links to Anxiety and Depression (GLAD)  
128 Study. In summary, individuals from the general population in the UK were recruited using  
129 a combination of traditional and social media, as well as clinic-based recruitment, based on  
130 the eligibility criterion of meeting a DSM-5 diagnosis for major depressive disorder (MDD)  
131 or any anxiety disorder. Participants were invited to complete online sign-up questionnaires,  
132 covering demographics, illness, and psychological and behavioural phenotypes relevant to  
133 anxiety and depression. Subsequently, participants filled out additional questionnaires that  
134 more deeply detailed medication use, psychiatric disorders beyond depression and anxiety,  
135 lifestyle, and personal history. A more comprehensive description can be found in Davies et  
136 al<sup>19</sup>. GLAD received ethical approval from the London - Fulham Research Ethics Committee  
137 (REC reference: 18/LO/1218), while the NIHR BioResource obtained approval from the East  
138 of England - Cambridge Central Committee (REC reference: 17/EE/0025).

139

### 140 **Polygenic score (PGS)**

141 Detailed genotyping and imputation steps can be found in [Supplementary Methods](#). Imputed  
142 genotypes were aligned with the Hapmap3 reference panel to remove strand-ambiguous  
143 SNPs and for PGS calculation. PGSs were computed using MegaPRS<sup>20</sup> via the GenoPred  
144 pipeline<sup>21</sup>. PGSs were reference standardised: MegaPRS was used to first construct PGS  
145 in the 1000 Genome European reference panel, following which the mean and standard  
146 deviation of PGS output in GLAD samples were scaled to the mean and standard deviation  
147 of the reference. GWAS summary statistics from 102 traits were incorporated for both  
148 reference PGSs and GLAD PGSs in this study ([Supplementary Table 1](#)). PGSs from the  
149 GLAD were further rescaled using the reference PGSs to ensure a comparable distribution  
150 with the reference.

151

### 152 **Inferred cytochrome metabolic phenotypes**

153 We selected CYP2C19 and CYP2D6 to examine their pharmacogenetic effects, as  
154 suggested by the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline  
155 for SSRIs and Tricyclic antidepressants<sup>22,23</sup>. Phasing was conducted using SHAPEIT4  
156 software for the regions of CYP2C19 and CYP2D6 obtained from PharmGKB  
157 (<https://www.pharmgkb.org/>)<sup>24</sup>. Star alleles were identified by SNPs matched between the  
158 phased data and CPIC definitions (<https://cpicpgx.org/>; downloaded June 2022)<sup>25</sup>. Allele  
159 function and activity values were annotated to include alleles with no, decreased, normal,  
160 and increased function (<https://cpicpgx.org/>)<sup>22</sup>. Metabolic phenotypes of CYP2C19,  
161 including poor, intermediate, normal, rapid/ultrarapid, were inferred from genotypes, and  
162 classified based on CPIC guidelines. CYP2D6 phenotypes (poor, intermediate, normal)  
163 were defined by the consensus recommendations of CPIC and the Dutch Pharmacogenetics  
164 Working Group (DPWG)<sup>26</sup>. Since structural variants of CYP2D6 were unavailable in the  
165 imputed genotype data, no rapid/ultrarapid metabolisers were identified. The activity score  
166 was determined by summing the activity values of the two star alleles in each individual.

167

### 168 **Outcomes**

169 Participants provided self-reported side effect data for commonly prescribed  
170 antidepressants in the UK, including eight selective serotonin reuptake inhibitors (SSRIs), 2  
171 serotonin and norepinephrine reuptake inhibitors (SNRIs), and 10 tricyclic antidepressants

172 (TCAs) ([Supplementary Table 2](#)). Participants were asked about any experienced side  
173 effects from the prescribed antidepressants and then selected one or more side effects from  
174 a list of 30 common symptoms, including *dry mouth, sweating, nausea, vomiting, diarrhoea,*  
175 *constipation, headache, dizziness, memory problems, attention/concentration difficulties,*  
176 *shaking, muscle pain, sleepiness/drowsiness, difficulty getting to sleep, increased anxiety,*  
177 *fast heartbeat, restlessness/agitation, fatigue or weakness, changes in appetite, weight gain,*  
178 *weight loss, itching, rash, runny nose, reduced sexual desire/function, menstrual*  
179 *problems/irregularities, blurred vision, suicidal thoughts, attempted suicide, and others.*  
180 Discontinuation was indicated by the response to whether the participant had to stop taking  
181 the antidepressant due to side effects.

182

183 Antidepressants were ordered by the age at which they were prescribed for each participant.  
184 In this study, we included antidepressants prescribed in the first and the most recent (last)  
185 year. Information on side effects and discontinuation due to side effects were collected for  
186 each antidepressant of each individual. To minimise self-report errors, we limited  
187 participants to those who reported at most three different antidepressants during both the  
188 first and the last year. Specifically, for first year antidepressants, we focused on whether  
189 each participant experienced any side effects or discontinuation with SSRI drugs. For last  
190 year antidepressants, we considered the occurrence of side effects and discontinuation for  
191 SSRI, SNRI, and TCA antidepressants. In cases where participants were prescribed more  
192 than one antidepressant within the same class in either year, side effects and  
193 discontinuation were counted if they occurred with either one of the drugs.

194

## 195 **Predictors**

196 We curated 259 items across five categories, including demographics, illness, clinical  
197 evaluation, antidepressant history, and genetics, to serve as predictor variables. Core  
198 demographic details (e.g., sex, employment status, years of education, marital status, BMI)  
199 and health conditions (neurological, allergic, cardiovascular, respiratory, digestive,  
200 inflammatory, cancer-related) were obtained from the sign-up questionnaire. Clinical and  
201 psychiatric symptoms were assessed through various measures, including lifetime  
202 measures of MDD and anxiety (adapted from the Composite International Diagnostic  
203 Interview - Short Form (CIDI-SF)), Standardised Assessment of the Severity of Personality  
204 Disorders (SASPD), and lifetime assessment of panic disorder (adapted from DSM-5/ICD-  
205 11 checklists). In terms of antidepressant histories, we considered antidepressant initiation  
206 and last prescription age, the total number and duration of antidepressants taken, and the  
207 average number of side effect occurrence, discontinuation, and efficacy (effectiveness of  
208 each antidepressant) calculated from all antidepressants taken before the last year. Genetic  
209 factors included PGSs for 102 traits and cytochrome metabolic phenotypes, as described  
210 above. The complete list of predictors was provided in [Supplementary Table 3](#).

211 To ensure all predictors in the model have been characterised before the outcome,  
212 we chose predictors that preceded the antidepressant initiation including all genetic  
213 variables, sex, ethnicity, antidepressant initiation age, lifetime depression and anxiety  
214 symptoms to predict outcomes of antidepressants taken in the first year. All predictors were  
215 added to the model for the prediction of antidepressants taken in the last year.

216

## 217 **Prediction modelling**

### 218 **– Data processing**

219 We removed predictors with missing values > 30%. The remaining were imputed using the  
220 random forest algorithm in the MICE package<sup>27</sup>. Predictors with either zero variance or a  
221 correlation higher than 0.8 with another predictor were excluded. For categorical factors with  
222 more than two categories, they were converted into a set of binary dummy variables in the  
223 elastic net and SVM models. Normalisation was applied to each predictor to achieve a  
224 standard deviation of one and a mean of zero before training the SVM.

225

### 226 **-- Model building**

227 We applied six prediction models, including elastic net, support vector machine (SVM) with  
228 radial basis function (RBF) and polynomial kernels, XGBoost, random forest, and cubist in  
229 this study. A stratified split was employed based on the outcome, randomly allocating 80%  
230 for the training data and the remaining 20% for the testing data, maintaining the same  
231 outcome proportions as in the original population in each split. Within the training data, a 5-  
232 fold stratified cross-validation with 5 repeats were conducted, assigning 20% of the data as  
233 a validation set for hyperparameter prioritisation and the remainder for model training. The  
234 receiver operating characteristic area under the curve (AUROC) was assessed in the  
235 validation set to identify models that maximise performance. The best performing models,  
236 along with their hyperparameter combinations, were extracted and employed to predict the  
237 outcome class in the test data. Beyond AUROC, we reported accuracy and precision-recall  
238 area under the curve (AUPRC) of test data for each model. After model training, a logistic  
239 regression was fitted between the probability estimates and the true probabilities to produce  
240 the calibrated estimates. More description of each model and data processing can be found  
241 in [Supplementary Methods](#).

242

### 243 **-- Feature importance**

244 For every predictor category (genetics, demographics, illness, clinical and antidepressant  
245 information) in the outcomes of drug prescriptions during the last year, we evaluated their  
246 importance by excluding the corresponding category of predictors and retrained the model  
247 using the same strategy for model building and estimation as described above. The relative  
248 reduction in AUROC was calculated for each predictor category compared to the models  
249 with the complete set of predictors.

250

### 251 **-- Prediction across antidepressant classes**

252 For each antidepressant class in the last year of prescription, we compared the model  
253 performance between the same drug (training and testing data within the same drug class)  
254 and cross drug (training and testing data across different drug classes) analyses to  
255 determine the specificity of the model to the drug class. The models with the best  
256 performance, identified through the same drug analysis, were then tested on data from other  
257 drugs. The Kruskal-Wallis test was used to examine the differences in AUROC values  
258 obtained from the same antidepressant class and cross-class analyses.

259

## 260 **Association of side effects with predictors at the last prescription**

261 To further make each predictor's effect more interpretable and understandable, a univariate  
262 logistic regression was performed between each predictor and the six outcomes at the last  
263 prescription to evaluate their associations. The false discovery rate was used to adjust the  
264 statistical significance for each outcome.

## 265 266 **Correlation of side effect symptoms and drug effect difference**

267 Tetrachoric correlations were applied to assess the correlation of side effect symptoms  
268 among SSRIs, SNRIs, and TCAs. Each side effect symptom was coded as a binary variable,  
269 with 1 indicating the occurrence of the symptom with any prescribed drugs and 0 showing  
270 the absence of the symptom. Hierarchical clustering analysis measured by Euclidean  
271 distance was conducted on the distance matrix derived from the correlation matrix of the  
272 symptoms. A generalised linear mixed model was constructed to investigate the impact of  
273 drug class on each side effect symptom, with drug class as a fixed variable and individual  
274 ID as a random variable. SSRIs were set as the reference for comparison with SNRIs and  
275 TCAs. Statistical significance was adjusted using the Bonferroni test across the 30  
276 symptoms.

277  
278 All prediction modelling and association analyses were performed using R v4.2.3<sup>28</sup>.

## 279 280 **Results**


### 281 **Participant characteristics**

282 All participants in this study were part of the Genetic Links to Anxiety and Depression (GLAD)  
283 Study. Overall, 8219 individuals completed the antidepressant questionnaire, and 5358 had  
284 available genetic data. In the first year of prescription, most individuals were prescribed  
285 SSRIs, with 45% continuing SSRIs and 19.0% transitioning to other antidepressants in the  
286 second prescription year ([Supplementary Figure 1](#)).

287  
288 The average prevalence of side effects and discontinuation during the initial five prescription  
289 years was 74% and 29%, respectively ([Figure 2](#)). In the first year, 6% of participants who  
290 initially experienced side effects reported none in the second year. Conversely, 20% of  
291 participants without side effects in the first year experienced at least one side effect symptom  
292 in the second year ([Supplementary Table 4](#)). For the discontinuation outcome, 33% of  
293 participants transitioned from discontinuation to no discontinuation in the first two years of  
294 prescription. Approximately 8% of participants experienced discontinuation in the second  
295 prescription year after having no discontinuation in the first year ([Supplementary Table 4](#)).

296  
297 For the prediction models, we included 4354 individuals for SSRIs in the first year of  
298 prescription. In addition, 3414 had data for an antidepressant prescription in the last year,  
299 comprising 60% (2036) on SSRIs, 22% (753) on SNRIs, and 29% (982) on TCAs. In the  
300 initial year, 73% of participants taking SSRIs experienced side effects, and 32% reported  
301 discontinuation. In the last year, the reported side effects prevalence for SSRIs was 75%,  
302 lower than SNRIs (84%) and TCAs (76%). Discontinuation was highest for TCAs (37%),  
303 followed by SSRIs (20.7%) and SNRIs (20.6%) ([Table 1](#)).





304  
305  
306  
307  
308  
309

Figure 2. Side effects and discontinuation occurrence at the first five years of prescription, where the x-axis represented each individual (ordered by yes first), and the y-axis showed the time of prescription.


Table 1. Side effects and discontinuation at the prescription of the first and last year

	Discontinuation	Side effect symptoms
Prescription at the first year (N (yes%))		
SSRI	3947 (31.6)	4286 (73.3)
Prescription at the last year (N (yes%))		
SSRI	1770 (20.7)	1986 (75.3)
SNRI	640 (20.6)	733 (83.5)
TCA	834 (37.2)	959 (76.4)

310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321

### Prediction of antidepressant side effects and discontinuation

In the initial year of SSRIs prescription, the best AUROCs for predicting discontinuation and side effects were 0.65 and 0.60, respectively, achieved by XGBoost (Figure 3a). In the last year of SSRIs prescription, the highest AUROC observed for discontinuation was 0.73, and 0.87 for side effects (Figure 3a). Models including elastic net, random forest and XGBoost achieved AUROC values around 0.70 for discontinuation and above 0.85 for side effects. For SNRIs, the best AUROC was observed in random forest, with 0.71 for discontinuation and 0.80 for side effects. The best models for TCAs had AUROC of 0.71 and 0.87 for predicting discontinuation and side effects, respectively (Supplementary Figure 2). More detailed results for AUROC, AUPRC and accuracy were provided in Supplementary Table 5.



328 Figure 3. ROC curve (a) and feature importance (b) of SSRIs discontinuation and side effects.  
 329 Antidepressant history included information of antidepressant initiation and last prescription age,  
 330 total number and duration of prescribed antidepressants, and the average number of efficacy ratings,  
 331 side effect occurrence, and discontinuation of all antidepressants taken before the last year of  
 332 prescription.

333  
 334 For the last year of prescription, we performed cross-class analysis to assess model  
 335 specificity, comparing the performance of the same training data when tested on different  
 336 antidepressant classes. For both discontinuation and side effects, the Kruskal-Wallis test  
 337 revealed no statistically significant differences between the same antidepressant class and  
 338 different classes for any drug-derived models. This suggested that these models were  
 339 nonspecific to antidepressant class in the last year of prescription (Supplementary Figure 3).


340  
 341 **Feature importance at the prescription of last year**  
 342 Next, for each drug class in the last prescription, we evaluated the importance of each  
 343 predictor category by removing corresponding categories one at a time and retrained the  
 344 model selected by the best performance of AUROC. We chose XGBoost in this step given  
 345 it showed superior performance on average across all outcomes described above. Overall,  
 346 antidepressant history emerged as the most influential category in predicting discontinuation  
 347 and side effects during the last year of prescription, with a relative reduction in AUROC  
 348 ranging from 11.4% to 24.0% for discontinuation and 20.4% to 37.1% for side effects (Figure  
 349 3b, Supplementary Figure 4). Other clinical measures made a modest contribution to the  
 350 model for discontinuation, with an impact of 10.0% in SSRIs, 1.4% in SNRIs, and 3.0% in  
 351 TCAs. Their impact on side effects was considerably less, with the highest relative AUROC  
 352 reduction of 1.0% in TCA drugs. Genetic factors exhibited the highest impact (1.1%) in  
 353 predicting side effects and 0.3% for discontinuation (Supplementary Figure 4).

354  
 355 **Association at the prescription of last year**

356 We also conducted univariate logistic regression to examine the association of side effects  
357 and discontinuation outcomes with individual features during the last year of prescription.  
358 As expected, we observed a strong association between side effect/ discontinuation history  
359 and both outcomes across all antidepressant classes ([Supplementary Figure 6](#)). For the  
360 discontinuation outcome, clinical measures related to depression (low mood, number of  
361 episodes, thoughts about death, group/talking therapy), anxiety (anxiety symptoms, duration  
362 of worry), and panic disorder (choking, strong fears of attack situations, panic symptoms,  
363 medical conditions) were linked to SSRIs, while no significance was observed in other drugs.  
364 For side effects, antidepressant prescription age and panic disorders (including panic  
365 symptoms, feeling hot or cold) showed associations across all drugs. Other features,  
366 including marital status, educational attainment, depressive symptoms, and panic symptoms  
367 (strong fears of attack situations, fear of losing control or going crazy, sweating) were  
368 associated with any two of the three antidepressant classes ([Supplementary Figure 6](#)).  
369

### 370 **Side effect symptoms correlation and drug specificity**

371 To investigate the correlations among side effect symptoms and identify how they differed  
372 across drug classes, we collected 30 common symptoms from the self-reported  
373 questionnaire. In [Figure 4](#), we present the prevalence of side effect symptoms for each drug  
374 class across all prescriptions. The most reported side effects included reduced sexual desire,  
375 dry mouth, sleepiness/drowsiness, and weight gain, while rash, runny nose, menstrual  
376 irregularities, and weight loss had the lowest prevalence. TCAs had most individuals  
377 reporting sleepiness/drowsiness, weight gain, dry mouth, and changes in appetite. Reduced  
378 sexual desire, nausea, dry mouth, and concentration difficulties were the most common  
379 symptoms of SSRIs. Reduced sexual desire, sweating, dry mouth, and nausea were  
380 predominantly reported in SNRIs ([Supplementary Table 6](#)).  
381



382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400


401

Figure 4. Prevalence of side effect symptoms in antidepressant classes. Symptoms were ordered by their prevalence in the studied population.

For individuals who reported more than one side effect symptom, we examined the correlations between these symptoms across medications. Significant correlations were evident between certain symptoms, such as nausea and vomiting ( $r = 0.797$ ), memory problems and concentration difficulties ( $r = 0.803$ ), itching and rash ( $r = 0.782$ ), as well as suicidal thoughts and attempted suicide ( $r = 0.861$ ). Moderate correlations were observed between sleepiness/drowsiness and fatigue or weakness ( $r = 0.663$ ), headache and dizziness ( $r = 0.653$ ), and a symptom cluster comprising increased anxiety, restlessness/agitation, and fast heart beat (increased anxiety vs restlessness/agitation:  $r = 0.743$ ; fast heart beat vs restlessness/agitation:  $r = 0.689$ ; fast heart beat vs increased anxiety:  $r = 0.639$ , [Supplementary Figure 6](#)).

Finally, we used generalised linear mixed models to investigate the impact of antidepressant classes on each side effect symptom. Compared to SSRIs, SNRIs and TCAs were associated with fewer reports of symptoms like suicidal thoughts, attempted suicide, increased anxiety, diarrhoea, weight loss, vomiting, restlessness/agitation, reduced sexual desire, rash, headache, and difficulty getting to sleep. Conversely, constipation showed a

402 higher occurrence in both SNRIs and TCAs compared to SSRIs. Symptoms such as weight  
 403 gain, sleepiness/drowsiness, fatigue or weakness, and changes in appetite were more likely  
 404 to occur in TCAs than SSRIs but were comparable between SNRIs and SSRIs. Dry mouth  
 405 and concentration difficulties showed no significant differences across all drugs (Figure 5,  
 406 [Supplementary Table 7](#)).  
 407



408  
 409 Figure 5. Association of side effect symptoms with drug classes using SSRIs as reference. Each bar  
 410 represents the effect of SNRIs/TCAs on side effect symptoms compared to SSRIs with 95%  
 411 confidence intervals.  
 412

413 **Discussion**

414 In this study, we find evidence that self-reported side effects and discontinuation (due to  
 415 side effects) can be predicted using questionnaires and genetic information, particularly for  
 416 the most recent antidepressant treatments. Among all predictors, antidepressant history  
 417 including side effects and discontinuation history showed the primary contribution, indicating  
 418 individuals tend to have consistent side effect occurrence across different prescriptions.  
 419 When examining 30 common antidepressant side effect symptoms, the most prevalent  
 420 symptoms were lower sexual desire, dry mouth, and sleepiness/drowsiness. Most of the 30  
 421 symptoms were differentially prevalent between antidepressant classes.  
 422

423 Using machine learning, our results confirmed predicting side effect occurrence was more  
424 accurate for the last antidepressant prescription compared to the initial treatment,  
425 particularly when considering antidepressant history. Relatively few studies have  
426 investigated how drug history influences adverse reactions to the current treatment.  
427 However, similar findings are reported in the available literature. For example, the risk of  
428 gastrointestinal side effects in nonsteroidal anti-inflammatory drugs (NSAIDs) could be  
429 increased if previous NSAID intolerance was identified<sup>29</sup>. In hospitalised older patients, a  
430 history of experiencing harmful outcomes from medications in the preceding year was shown  
431 to predict adverse drug effects from current medications<sup>30</sup>. A study on treatment-resistant  
432 depression also found that a history of electroconvulsive therapy and unsuccessful  
433 antidepressant trials were associated with the outcome of vagus nerve stimulation<sup>31</sup>. Despite  
434 this, medication history of side effects and discontinuation has been largely overlooked in  
435 prediction studies.

436  
437 Antidepressant side effects have been linked to the severity of depression, polypharmacy,  
438 and comorbid status<sup>8,32,33</sup>. Similarly, we observed that clinical measures such as a higher  
439 score of depression/panic symptoms and number of episodes could increase the risk of side  
440 effects and discontinuation, but their effects were less pronounced than the impact of side  
441 effects or discontinuation history. We also identified a large correlation of side effect history  
442 among antidepressant classes above 0.62 (SSRIs vs SNRIs:  $r = 0.66$ , SSRIs vs TCAs:  $r =$   
443  $0.68$ , SNRIs vs TCAs:  $r = 0.62$ ), suggesting the occurrence of self-reported side effects might  
444 be underlined by other factors regardless of antidepressant class, such as pharmacological,  
445 or genetic factors, as indicated in other studies<sup>11</sup>. The role of other factors such as  
446 expectation bias should also be considered, especially when using self-reported data<sup>33</sup>.

447  
448 Genetic predictors, including pharmacokinetic features (*CYP2C19* and *CYP2D6* metabolic  
449 phenotypes) along with polygenic risk for multiple disorders and traits only marginally  
450 improved model performance in the last prescription. This finding aligned with Poweleit et  
451 al.<sup>18</sup>, where the predictive ability of *CYP2C19* phenotypes was limited compared to  
452 pharmacokinetic parameters including clearance, half-life for escitalopram and sertraline  
453 side effects. *CYP2C19* poor metabolisers exhibited an OR of 1.99 for the occurrence of the  
454 last SSRI side effect in our univariate association analysis, showing a comparable effect  
455 size to other studies<sup>10,34</sup>. However, statistical significance was not achieved due to limited  
456 power. We did not find an association between *CYP2D6* metabolic status and any side effect  
457 outcomes and it is important to note that the genotype-determined metabolic phenotype in  
458 our study has a lower ability to identify star alleles, particularly for *CYP2D6*. Approximately  
459 7% of *CYP2D6* variants are structural variants, so the star allele calls and metabolic  
460 phenotype imputation would be influenced by these missing variants in the genotype leading  
461 to the misclassification of metabolic phenotypes and higher false negative findings<sup>25,35</sup>.

462  
463 We observed a modest predictive ability of PGSs for side effects and discontinuation.  
464 Previous studies have reported PGSs for depression, schizophrenia, attention-deficit  
465 hyperactivity disorder, and bipolar disorder with treatment response or resistance, but these  
466 results mostly yielded no strong evidence of significant associations<sup>36,37</sup>. A study showed  
467 PGSs were associated with corresponding side effect symptoms, such as the PGS for

468 depression was linked to depressive symptoms including suicidality and anxiety, and the  
469 BMI PGS was associated with weight gain side effects<sup>11</sup>. However, the explained variance  
470 attributed to these PGSs (approximately 1%) to predict side effect outcomes was low.  
471 Although our study integrated multiple PGS traits to enhance prediction power<sup>12</sup>, we lacked  
472 PGSs directly related to antidepressant side effects or responses, which need to be the  
473 subject of larger studies<sup>37</sup>. We also acknowledge the need for a larger sample size to fully  
474 reflect their predictive ability<sup>38</sup>. Genetic contribution to antidepressant side effects would be  
475 further improved with more precise measures of pharmacogenomic phenotypes and  
476 sufficient sample size to maximise the PGS evaluation.

477

478 As mentioned above, the most commonly reported side effects included reduced sexual  
479 desire, dry mouth, sleepiness/drowsiness, and weight gain – consistent with findings from  
480 other studies<sup>1,32</sup>. Some symptoms, such as dry mouth, were common in all antidepressant  
481 classes, while others, such as reduced sexual desire, were mostly associated with SSRIs  
482 or SNRIs, and drowsiness was most prevalent in TCAs. Previous studies have indicated  
483 SSRIs were associated with gastrointestinal symptoms, anxiety, insomnia, and sexual side  
484 effects, and TCAs broadly conferred an increased risk of weight gain, sedation, sexual  
485 dysfunction, and anticholinergic symptoms<sup>4,6,32,39,40</sup>. We confirmed SSRIs were more likely  
486 to cause gastrointestinal symptoms (vomiting, diarrhoea, nausea), restlessness agitation,  
487 anxiety, weight loss, reduced sexual desire, and difficulty getting to sleep, while individuals  
488 taking TCAs experienced more weight gain, sleepiness/drowsiness, change in appetite, and  
489 fatigue or weakness. Anticholinergic symptoms such as constipation were more common  
490 with TCAs than SSRIs while dry mouth and concentration difficulties showed no differences  
491 among drug classes.

492

493 We found suicidality (attempted suicide and suicidal thoughts) was mostly reported in SSRIs  
494 compared to SNRIs or TCAs. The FDA has added a black box warning for increased  
495 suicidality risk among adolescents aged 18-24 with SSRIs prescription<sup>4,41</sup>. However, the  
496 effectiveness of this warning is disputed, given increased suicidality among those with  
497 severe depression who were not prescribed antidepressants as a result of the warning<sup>42</sup>.  
498 While SSRIs were found to increase the risk of suicidality when prescribed for adolescents,  
499 the risk was reduced in adults<sup>40</sup>. Among people aged 20 or older when prescribed  
500 antidepressants, there was no significant difference in rates of attempted suicide and self-  
501 harm between SSRIs and TCAs<sup>43,44</sup>. When stratifying by age, we found that the difference  
502 in the rate of attempted suicide between SSRIs and TCAs was more pronounced in  
503 individuals younger than 25 than in older participants ([Supplementary Table 8](#)). Given the  
504 retrospective reporting of prescriptions and side effects in our study of a relatively severe  
505 study sample, individuals who had suicidal behaviour after taking antidepressants may have  
506 failed to respond leading to a potential ‘survivorship bias’ of our samples. Thus, our results  
507 should be interpreted with caution with more evidence needed from other studies.

508

509 Our study provides a unique resource to explore the contribution of genetic and medical  
510 factors on antidepressant side effects using one of the most powerful and comprehensive  
511 self-report records available. Nonetheless, some limitations should be considered. In  
512 addition to incomplete metabolic phenotype imputation and limited polygenic prediction due

513 to available PGSs and sample size mentioned above, the retrospective study design with  
514 self-report phenotype is prone to subjective interpretations and recall bias. In the GENDEP  
515 clinical trial, antidepressant side effects were shown to be reliably measured with self-report  
516 instruments, via good agreement with psychiatrists' ratings. However, this evaluation was  
517 limited to the trial period<sup>32</sup>. Linking our data to electronic medical records would allow us to  
518 track individuals' antidepressant trajectories through their lifetime with a more precise  
519 assessment compared to self-report<sup>45</sup>. Illness perceptions related to antidepressant  
520 medication are not available in our data which may be predictive of treatment adherence or  
521 continuation<sup>46</sup>. In addition, our data recorded by age did not distinguish whether  
522 antidepressants were prescribed simultaneously or not within the same year. Non-  
523 antidepressant medication data was unavailable limiting the evaluation of polypharmacy  
524 effects. We also did not collect detailed information on antidepressant dosage, atypical  
525 antidepressants (such as Bupropion, Trazodone), or rarer side effects such as myocardial  
526 infarction. Finally, our study lacks external validation of models in an independent sample.  
527 As our results are primarily based on individuals of European ancestry, further analyses are  
528 necessary when generalising our findings to other populations with distinct genetic and  
529 social backgrounds.

530  
531 In conclusion, our study highlighted that self-reported antidepressant side effects and  
532 discontinuation can be predicted by incorporating genetic and medical phenotype  
533 information, with antidepressant history being a crucial feature. While genetic predictors  
534 showed a minor impact, larger samples for discovery GWAS of antidepressant phenotypes  
535 and advancements in genetics such as long-read sequencing are needed to fully capture  
536 their predictive ability. In our analysis, individuals report experiencing different side effect  
537 symptoms across antidepressant classes. Further studies with detailed information on  
538 antidepressant regimens and combined treatments will enable a full assessment of  
539 antidepressant trajectories and the identification of genetic and clinical risk stratification for  
540 potential individualised clinical applications.

541

#### 542 **Data and code availability**

543 The GLAD study data are available via a data request application to the NIHR BioResource  
544 ([https://bioresource.nihr.ac.uk/using-our-bioresource/academic-and-clinical-  
545 researchers/apply-for-bioresource-data/](https://bioresource.nihr.ac.uk/using-our-bioresource/academic-and-clinical-researchers/apply-for-bioresource-data/)).

546

#### 547 **Funding**

548 This work was supported by the National Institute for Health and Care Research (NIHR)  
549 BioResource [RG94028, RG85445], NIHR Biomedical Research Centre [IS-BRC-1215-  
550 20018], HSC R&D Division, Public Health Agency [COM/5516/18], MRC Mental Health Data  
551 Pathfinder Award (MC\_PC\_17,217), and the National Centre for Mental Health funding  
552 through Health and Care Research Wales. Dr Hübel acknowledges funding from  
553 Lundbeckfonden (R276-2018-4581). Johan Källberg Zvrskovec acknowledges funding from  
554 the National Institute for Health and Care Research (NIHR) Biomedical Research Centre  
555 and Guy's and St Thomas' NHS Foundation Trust. Prof McIntosh received funding from the  
556 Wellcome Trust (226770/Z/22/Z).

557



## 558 **Conflict of interest**

559 Prof Breen has received honoraria, research or conference grants and consulting fees from  
560 Illumina, Otsuka, and COMPASS Pathfinder Ltd. Prof Hotopf is the principal investigator of  
561 the RADAR-CNS consortium, an IMI public private partnership, and as such receives  
562 research funding from Janssen, UCB, Biogen, Lundbeck and MSD. Prof McIntosh has  
563 received research support from Eli Lilly, Janssen, and the Sackler Foundation, and has also  
564 received speaker fees from Illumina and Janssen.

## 566 **Acknowledgements**

567 We thank the GLAD Study and NIHR BioResource volunteers for their participation and  
568 gratefully acknowledge the NIHR BioResource centres, NHS Trusts, and staff for their  
569 contribution. We thank the National Institute for Health Research, and Health Data Research  
570 UK as part of the Digital Innovation Hub Programme. This study presents independent  
571 research funded by the NIHR Biomedical Research Centre at South London Maudsley NHS  
572 Foundation Trust and King's College London. Further information can be found at  
573 <http://brc.slam.nhs.uk/about/core-facilities/bioresource>. The views expressed are those of  
574 the authors and not necessarily those of the NHS, the NIHR, the HSC R&D Division, King's  
575 College London, or the Department of Health and Social Care.



## 577 **References**

- 578 1. Kelly, K., Posternak, M. & Jonathan, E. A. Toward achieving optimal response: understanding  
579 and managing antidepressant side effects. *Dialogues in Clinical Neuroscience* **10**, 409–418  
580 (2008).
- 581 2. Sansone, R. A. & Sansone, L. A. Antidepressant Adherence: Are Patients Taking Their  
582 Medications? *Innovations in Clinical Neuroscience* **9**, 41–46 (2012).
- 583 3. Hillhouse, T. M. & Porter, J. H. A brief history of the development of antidepressant drugs:  
584 From monoamines to glutamate. *Experimental and Clinical Psychopharmacology* **23**, 1–21  
585 (2015).
- 586 4. Wang, S.-M. *et al.* Addressing the Side Effects of Contemporary Antidepressant Drugs: A  
587 Comprehensive Review. *Chonnam Med J* **54**, 101 (2018).
- 588 5. Hotopf, M., Hardy, R. & Lewis, G. Discontinuation rates of SSRIs and tricyclic antidepressants:  
589 a meta-analysis and investigation of heterogeneity. *Br J Psychiatry* **170**, 120–127 (1997).
- 590 6. Millan, M. J. Multi-target strategies for the improved treatment of depressive states: Conceptual  
591 foundations and neuronal substrates, drug discovery and therapeutic application.  
592 *Pharmacology & Therapeutics* **110**, 135–370 (2006).
- 593 7. Kornstein, S. G. *et al.* Gender Differences in Treatment Response to Sertraline Versus  
594 Imipramine in Chronic Depression. *AJP* **157**, 1445–1452 (2000).
- 595 8. De Las Cuevas, C., Peñate, W. & Sanz, E. J. Risk factors for non-adherence to antidepressant  
596 treatment in patients with mood disorders. *Eur J Clin Pharmacol* **70**, 89–98 (2014).
- 597 9. Maggo, S. *et al.* Common CYP2D6, CYP2C9, and CYP2C19 Gene Variants, Health Anxiety,  
598 and Neuroticism Are Not Associated With Self-Reported Antidepressant Side Effects. *Frontiers*  
599 *in Genetics* **10**, 1199 (2019).
- 600 10. Fabbri, C. *et al.* Effect of cytochrome CYP2C19 metabolizing activity on antidepressant  
601 response and side effects: Meta-analysis of data from genome-wide association studies.  
602 *European Neuropsychopharmacology* **28**, 945–954 (2018).
- 603 11. Campos, A. I. *et al.* Understanding genetic risk factors for common side effects of  
604 antidepressant medications. *Commun Med* **1**, 45 (2021).
- 605 12. Albiñana, C. *et al.* Multi-PGS enhances polygenic prediction by combining 937 polygenic  
606 scores. *Nat Commun* **14**, 4702 (2023).
- 607 13. Krapohl, E. *et al.* Multi-polygenic score approach to trait prediction. *Mol Psychiatry* **23**, 1368–  
608 1374 (2018).



- 609 14. Bzdok, D., Varoquaux, G. & Steyerberg, E. W. Prediction, Not Association, Paves the Road to  
610 Precision Medicine. *JAMA Psychiatry* **78**, 127 (2021).
- 611 15. Bzdok, D., Altman, N. & Krzywinski, M. Points of Significance: Statistics versus machine  
612 learning. *Nature Methods* **15**, 233–234 (2018).
- 613 16. Denck, J., Ozkirimli, E. & Wang, K. Machine-learning-based adverse drug event prediction  
614 from observational health data: A review. *Drug Discovery Today* **28**, 103715 (2023).
- 615 17. Sajjadian, M. *et al.* Machine learning in the prediction of depression treatment outcomes: a  
616 systematic review and meta-analysis. *Psychol. Med.* **51**, 2742–2751 (2021).
- 617 18. Poweleit, E. A. *et al.* Machine Learning-Based Prediction of Escitalopram and Sertraline Side  
618 Effects with Pharmacokinetic Data in Children and Adolescents. *Clin Pharma and Therapeutics*  
619 *cpt.3184* (2024) doi:10.1002/cpt.3184.
- 620 19. Davies, M. R. *et al.* The Genetic Links to Anxiety and Depression (GLAD) Study: Online  
621 recruitment into the largest recontactable study of depression and anxiety. *Behaviour*  
622 *Research and Therapy* **123**, 103503 (2019).
- 623 20. Zhang, Q., Privé, F., Vilhjálmsson, B. & Speed, D. Improved genetic prediction of complex  
624 traits from individual-level data or summary statistics. *Nat Commun* **12**, 4192 (2021).
- 625 21. GenoPred at github. <https://github.com/opain/GenoPred>.
- 626 22. Bousman, C. A. *et al.* Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline  
627 for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake  
628 Inhibitor Antidepressants. *Clin Pharma and Therapeutics* **114**, 51–68 (2023).
- 629 23. Hicks, J. K. *et al.* Clinical pharmacogenetics implementation consortium guideline (CPIC) for  
630 CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.  
631 *Clinical Pharmacology & Therapeutics* **102**, 37–44 (2017).
- 632 24. Delaneau, O., Zagury, J.-F., Robinson, M. R., Marchini, J. L. & Dermitzakis, E. T. Accurate,  
633 scalable and integrative haplotype estimation. *Nat Commun* **10**, 5436 (2019).
- 634 25. Li, D. *et al.* Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant  
635 response from 13 clinical studies using genotype imputation. Preprint at  
636 <https://doi.org/10.1101/2023.06.26.23291890> (2023).
- 637 26. Caudle, K. E. *et al.* Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus  
638 Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch  
639 Pharmacogenetics Working Group. *Clinical and Translational Science* **13**, 116–124 (2020).
- 640 27. Buuren, S. V. & Groothuis-Oudshoorn, K. mice: Multivariate Imputation by Chained Equations  
641 in R. *J. Stat. Soft.* **45**, (2011).
- 642 28. R Core Team. R: A language and environment for statistical computing. R Foundation for  
643 Statistical Computing (2023).
- 644 29. Griffin, M. R. Epidemiology of Nonsteroidal Anti-inflammatory Drug–Associated Gastrointestinal  
645 Injury. *The American Journal of Medicine* **104**, 23S-29S (1998).
- 646 30. Yadesa, T. M., Kitutu, F. E., Tamukong, R. & Alele, P. E. Predictors of hospital-acquired  
647 adverse drug reactions: a cohort of Ugandan older adults. *BMC Geriatr* **22**, 359 (2022).
- 648 31. Sackeim, H. Vagus Nerve Stimulation (VNS™) for Treatment-Resistant Depression Efficacy,  
649 Side Effects, and Predictors of Outcome. *Neuropsychopharmacology* **25**, 713–728 (2001).
- 650 32. Uher, R. *et al.* Adverse reactions to antidepressants. *Br J Psychiatry* **195**, 202–210 (2009).
- 651 33. Rheker, J., Winkler, A., Doering, B. K. & Rief, W. Learning to experience side effects after  
652 antidepressant intake – Results from a randomized, controlled, double-blind study.  
653 *Psychopharmacology* **234**, 329–338 (2017).
- 654 34. Campos, A. I. *et al.* Impact of CYP2C19 metaboliser status on SSRI response: a retrospective  
655 study of 9500 participants of the Australian Genetics of Depression Study. *The*  
656 *Pharmacogenomics Journal* **22**, 130–135 (2022).
- 657 35. Del Tredici, A. L. *et al.* Frequency of CYP2D6 Alleles Including Structural Variants in the United  
658 States. *Front. Pharmacol.* **9**, 305 (2018).
- 659 36. Fusar-Poli, L., Rutten, B. P. F., Van Os, J., Aguglia, E. & Guloksuz, S. Polygenic risk scores for  
660 predicting outcomes and treatment response in psychiatry: hope or hype? *International Review*  
661 *of Psychiatry* **34**, 663–675 (2022).
- 662 37. Pain, O. *et al.* Identifying the Common Genetic Basis of Antidepressant Response. *Biological*  
663 *Psychiatry Global Open Science* **2**, 115–126 (2022).

- 664 38. Dudbridge, F. Power and Predictive Accuracy of Polygenic Risk Scores. *PLoS Genet* **9**,  
665 e1003348 (2013).
- 666 39. Pillinger, T. *et al.* Antidepressant and antipsychotic side-effects and personalised prescribing: a  
667 systematic review and digital tool development. *The Lancet Psychiatry* **10**, 860–876 (2023).
- 668 40. Reid, S. & Barbui, C. Long term treatment of depression with selective serotonin reuptake  
669 inhibitors and newer antidepressants. *BMJ* **340**, c1468–c1468 (2010).
- 670 41. Edinoff, A. N. *et al.* Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative  
671 Review. *Neurology International* **13**, 387–401 (2021).
- 672 42. Fornaro, M. *et al.* The FDA “Black Box” Warning on Antidepressant Suicide Risk in Young  
673 Adults: More Harm Than Benefits? *Front. Psychiatry* **10**, 294 (2019).
- 674 43. Coupland, C. *et al.* Antidepressant use and risk of adverse outcomes in older people:  
675 population based cohort study. *BMJ* **343**, d4551–d4551 (2011).
- 676 44. Coupland, C. *et al.* Antidepressant use and risk of suicide and attempted suicide or self harm in  
677 people aged 20 to 64: cohort study using a primary care database. *BMJ* **350**, h517–h517  
678 (2015).
- 679 45. Smoller, J. W. The use of electronic health records for psychiatric phenotyping and genomics.  
680 *American J of Med Genetics Pt B* **177**, 601–612 (2018).
- 681 46. Hunot, V. M., Horne, R., Leese, M. N. & Churchill, R. C. A Cohort Study of Adherence to  
682 Antidepressants in Primary Care: The Influence of Antidepressant Concerns and Treatment  
683 Preferences. *Prim. Care Companion J. Clin. Psychiatry* **09**, 91–99 (2007).
- 684

## Side effect outcome




## Prediction model





### Side effect



### Discontinuation



No Yes

**a.****b.**

- Cubist
- Elastic net
- SVM Poly
- Random forest
- SVM RBF
- XGBoost








Table 1. Side effects and discontinuation at the prescription of the first and last year

	<b>Discontinuation</b>	<b>Side effect symptoms</b>
Prescription at the first year (N (yes%))		
SSRI	3947 (31.6)	4286 (73.3)
Prescription at the last year (N (yes%))		
SSRI	1770 (20.7)	1986 (75.3)
SNRI	640 (20.6)	733 (83.5)
Tricyclic	834 (37.2)	959 (76.4)